Clinical trials with oncolytic adenovirus in China
- PMID: 17346105
- DOI: 10.2174/156800907780058817
Clinical trials with oncolytic adenovirus in China
Abstract
Since the 1990s, oncolytic viruses were utilized to treat cancer patients from phase I to phase III. Oncolytic virus development in China has been keeping in step with that in other countries and even accelerated the process in some fields, especially in conducting clinical trials. H101 is one kind of oncolytic adenovirus with E1B-55KD and partial E3 deleted developed by Shanghai Sunwaybio. From 2000-2004, phase I to phase III clinical trials for treating head and neck cancer were conducted in China. Clinical data show that H101 is well tolerable and has good efficacy when combined with chemotherapy in some cancer treatment modalities. We review the clinical results and relative issues of H101 in treating cancer and discuss approaches and possible improvements for the future. Information on other oncolytic viruses developing in China is also provided.
Similar articles
-
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.Gene Ther. 2005 Sep;12(17):1333-46. doi: 10.1038/sj.gt.3302555. Gene Ther. 2005. PMID: 15920462
-
Oncolytic Replication of E1b-Deleted Adenoviruses.Viruses. 2015 Nov 6;7(11):5767-79. doi: 10.3390/v7112905. Viruses. 2015. PMID: 26561828 Free PMC article. Review.
-
[Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer].Ai Zheng. 2003 Dec;22(12):1307-10. Ai Zheng. 2003. PMID: 14693057 Clinical Trial. Chinese.
-
[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].Ai Zheng. 2004 Dec;23(12):1666-70. Ai Zheng. 2004. PMID: 15601557 Clinical Trial. Chinese.
-
From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.Curr Cancer Drug Targets. 2007 Mar;7(2):133-9. doi: 10.2174/156800907780058862. Curr Cancer Drug Targets. 2007. PMID: 17346104 Review.
Cited by
-
The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment In Vitro.Cells. 2024 Feb 17;13(4):351. doi: 10.3390/cells13040351. Cells. 2024. PMID: 38391964 Free PMC article.
-
Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.J Transl Med. 2012 Jan 4;10:3. doi: 10.1186/1479-5876-10-3. J Transl Med. 2012. PMID: 22216938 Free PMC article. Review.
-
Recent Advances and Challenges in Uveal Melanoma Immunotherapy.Cancers (Basel). 2022 Jun 23;14(13):3094. doi: 10.3390/cancers14133094. Cancers (Basel). 2022. PMID: 35804863 Free PMC article. Review.
-
Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus.Hum Gene Ther. 2009 Sep;20(9):975-88. doi: 10.1089/hum.2009.028. Hum Gene Ther. 2009. PMID: 19469693 Free PMC article.
-
Viral vector platforms within the gene therapy landscape.Signal Transduct Target Ther. 2021 Feb 8;6(1):53. doi: 10.1038/s41392-021-00487-6. Signal Transduct Target Ther. 2021. PMID: 33558455 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
